The results of our preclinical study showed that WWP1 genetic or pharmacological inhibition enhanced the antitumor effects of SHP2 inhibitor, suggesting that the WWP1 inhibitor I3C may be a candidate for clinical trials to improve targeted therapies for advanced CRC patients. Here, WWP1 is linked to colorectal carcinoma.